MXPA01000830A - Un polinucleotido que comprende un elemento de abertura ubiculo de cromatina. - Google Patents

Un polinucleotido que comprende un elemento de abertura ubiculo de cromatina.

Info

Publication number
MXPA01000830A
MXPA01000830A MXPA01000830A MXPA01000830A MXPA01000830A MX PA01000830 A MXPA01000830 A MX PA01000830A MX PA01000830 A MXPA01000830 A MX PA01000830A MX PA01000830 A MXPA01000830 A MX PA01000830A MX PA01000830 A MXPA01000830 A MX PA01000830A
Authority
MX
Mexico
Prior art keywords
gene
expression
vector
cells
polynucleotide
Prior art date
Application number
MXPA01000830A
Other languages
English (en)
Spanish (es)
Inventor
Michael Antoniou
Original Assignee
Cobra Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815879.3A external-priority patent/GB9815879D0/en
Priority claimed from GBGB9906712.6A external-priority patent/GB9906712D0/en
Priority claimed from GBGB9909494.8A external-priority patent/GB9909494D0/en
Application filed by Cobra Therapeutics Ltd filed Critical Cobra Therapeutics Ltd
Publication of MXPA01000830A publication Critical patent/MXPA01000830A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MXPA01000830A 1998-07-21 1999-07-21 Un polinucleotido que comprende un elemento de abertura ubiculo de cromatina. MXPA01000830A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9815879.3A GB9815879D0 (en) 1998-07-21 1998-07-21 A polynucleotide
US10768898P 1998-11-09 1998-11-09
GBGB9906712.6A GB9906712D0 (en) 1999-03-23 1999-03-23 A polynucleotide
US12741099P 1999-04-01 1999-04-01
GBGB9909494.8A GB9909494D0 (en) 1999-04-23 1999-04-23 A plasmid
US13401699P 1999-05-12 1999-05-12
PCT/GB1999/002357 WO2000005393A2 (en) 1998-07-21 1999-07-21 A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)

Publications (1)

Publication Number Publication Date
MXPA01000830A true MXPA01000830A (es) 2002-06-04

Family

ID=27547316

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01000830A MXPA01000830A (es) 1998-07-21 1999-07-21 Un polinucleotido que comprende un elemento de abertura ubiculo de cromatina.

Country Status (8)

Country Link
EP (2) EP2348118A1 (enExample)
JP (4) JP4220673B2 (enExample)
KR (3) KR100795626B1 (enExample)
CN (1) CN100365127C (enExample)
AU (1) AU771111B2 (enExample)
CA (1) CA2333852C (enExample)
MX (1) MXPA01000830A (enExample)
WO (1) WO2000005393A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100996016B1 (ko) 2000-09-20 2010-11-22 밀리포어 코포레이션 폴리뉴클레오티드
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
CN102206633A (zh) * 2001-04-05 2011-10-05 密理博公司 改进的基因表达
WO2002081677A2 (en) * 2001-04-05 2002-10-17 Ml Laboratories Plc Improved gene expression
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
JP4489424B2 (ja) 2001-05-30 2010-06-23 グラクソ グループ リミテッド 染色体に基くプラットホーム
WO2002099070A2 (en) * 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
DE60237048D1 (de) 2001-07-04 2010-08-26 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
ATE443762T1 (de) 2002-01-09 2009-10-15 Minos Biosystems Ltd Induktierbare transposition beim transgenen organismus mit transposon-vektor
CA2489475C (en) 2002-06-14 2011-03-29 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
WO2003106674A2 (en) 2002-06-14 2003-12-24 Chromagenics B.V. Means and methods for regulating gene expression
DK1573058T3 (da) 2002-12-18 2012-01-16 Chromagenics Bv Fremgangsmåde til forbedring af proteinproduktion
DK1572994T3 (da) 2002-12-20 2007-05-29 Chromagenics Bv Midler og fremgangsmåder til fremstilling af en protein gennem chromatinåbnere, som kan göre chromatin mere tilgængeligt for transkriptionsfaktorer
ATE471988T1 (de) 2003-02-01 2010-07-15 Millipore Corp Verbesserte genetische elemente für eine erhöhte genexpression
KR101269656B1 (ko) 2003-10-24 2013-05-30 셀렉시스 에스. 에이. Ｍａｒ 서열의 복합 트랜스펙션 방법에 의한 포유동물 세포에서의 고효율 유전자 전달 및 발현
EP1702071B1 (en) * 2003-12-31 2012-02-22 Kalobios Inc. Transactivation system for mammalian cells
JP4926054B2 (ja) 2004-07-20 2012-05-09 シムフォゲン・アクティーゼルスカブ 抗−ＲｈＤ組換えポリクローナル抗体及び製造方法
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
NZ553700A (en) 2004-11-08 2010-09-30 Chromagenics Bv Selection of host cells expressing protein at high levels using a selectable marker with a non-optimal start codon
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
BRPI0517380A (pt) 2004-11-08 2008-10-07 Chromagenics Bv molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse
GB0504587D0 (en) 2005-03-05 2005-04-13 Ml Lab Plc Vectors comprising guinea pig CMV regulatory elements
GB0509965D0 (en) * 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
WO2007081336A1 (en) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Mammalian vectors for high-level expression of recombinant proteins
EP1996705B1 (en) 2006-03-20 2011-08-31 ChromaGenics B.V. Expression augmenting dna fragments, use thereof, and methods for finding thereof
WO2008085962A2 (en) * 2007-01-08 2008-07-17 Millipore Corporation Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
CN104531699B (zh) * 2014-10-09 2017-03-15 河南农业大学 一种增强外源基因表达的猪的ucoe调控元件片段
EP4589006A3 (en) * 2014-12-16 2025-08-13 Garvan Institute of Medical Research Sequencing controls
US11959093B2 (en) 2017-03-19 2024-04-16 Applied Stemcell, Inc. Integration sites and uses thereof
US10801021B2 (en) 2017-04-03 2020-10-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for multiplexed quantitative analysis of cell lineages
WO2019113378A1 (en) * 2017-12-07 2019-06-13 Integrity Biosolutions, Llc Engineered ubiquitous chromatin opening elements and uses thereof
KR102873620B1 (ko) * 2018-05-24 2025-10-21 국립대학법인 홋가이도 다이가쿠 신규 벡터 및 그 이용
JP7431802B2 (ja) 2018-08-15 2024-02-15 イルミナ インコーポレイテッド ライブラリー富化を改善するための組成物および方法
US20220304285A1 (en) * 2018-10-02 2022-09-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for multiplexed quantitative analysis of cell lineages
WO2020223160A1 (en) * 2019-04-30 2020-11-05 Chan Zuckerberg Biohub, Inc. A novel chromatin-opening element for stable long term gene expression
CN112575031B (zh) * 2019-09-29 2023-04-07 新乡医学院 一种遍在染色质开放表达元件、重组表达载体、表达系统及其制备方法、应用
CN116574735B (zh) * 2023-07-03 2023-11-10 艾米能斯(苏州)生物科技有限公司 一种多核苷酸及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
GB8718779D0 (en) 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
SG88714A1 (en) 1989-11-06 2002-05-21 Cell Genesys Inc Production of proteins using homologous recombination
WO1991017773A2 (de) 1990-05-18 1991-11-28 Boehringer Ingelheim International Gmbh Neue protein-polykation-konjugate
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
GB9109928D0 (en) 1991-05-08 1991-07-03 Interox Chemicals Ltd Thickened compositions
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
JPH07505283A (ja) 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン Ｄｎａトランスポーター系および使用方法
US5583009A (en) 1992-12-08 1996-12-10 University Of Washington Method of preparing recombinant proteins in transgenic animals containing metallothionein gene elements that bestow tissue-independent copy number-dependent, position-indepedent gene expression
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
WO1996041606A2 (en) 1995-06-08 1996-12-27 Therexsys Limited Improved pharmaceutical compositions for gene therapy
ATE199570T1 (de) 1996-08-16 2001-03-15 Medical Res Council Selbst-replizierende episomale expressionsvektoren, welche gewebespezifische expression vermitteln
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
ATE349465T1 (de) 1997-02-12 2007-01-15 Innovata Plc Zusammensetzungen sowie verfahren zur hocheffizienten transfektion

Also Published As

Publication number Publication date
CA2333852A1 (en) 2000-02-03
CN100365127C (zh) 2008-01-30
AU5053499A (en) 2000-02-14
KR20010083131A (ko) 2001-08-31
WO2000005393A2 (en) 2000-02-03
HK1035740A1 (en) 2001-12-07
EP1098986B1 (en) 2011-12-28
AU771111B2 (en) 2004-03-11
KR20090117675A (ko) 2009-11-12
JP2002522027A (ja) 2002-07-23
KR20070108336A (ko) 2007-11-09
JP2005052149A (ja) 2005-03-03
CN1334878A (zh) 2002-02-06
EP1098986A2 (en) 2001-05-16
EP2348118A1 (en) 2011-07-27
CA2333852C (en) 2007-05-29
JP4220673B2 (ja) 2009-02-04
KR100795626B1 (ko) 2008-01-17
WO2000005393A3 (en) 2000-08-17
JP2008109931A (ja) 2008-05-15
JP2009102331A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
US6689606B2 (en) Polynucleotide
CA2333852C (en) A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
CN1461343B (zh) 多核苷酸
US20040019923A1 (en) Exogenous proteins expressed in avians and their eggs
US20060171921A1 (en) Glycosylated interferon
US6949361B2 (en) Polynucleotide
CN101260384A (zh) 具有遍在染色质开放表达元件(ucoe)的聚核苷酸
HK1035740B (en) A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
Miyazaki Basic components of gene expression plasmids

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: EMD MILLIPORE CORPORATION

GB Transfer or rights

Owner name: EMD MILLIPORE CORPORATION

HC Change of company name or juridical status

Owner name: EMD MILLIPORE CORPORATION

GB Transfer or rights

Owner name: EMD MILLIPORE CORPORATION

FG Grant or registration
HC Change of company name or juridical status

Owner name: EMD MILLIPORE CORPORATION

MM Annulment or lapse due to non-payment of fees